Ivermectin

[키워드] activate acute respiratory distress syndrome Alpha alveolar Anti-inflammatory therapy Anti-viral anti-viral effect anticoagulant therapy anticoagulation approach ARDS ARDSacute respiratory distress syndrome Bacterial Beta Blood C-reactive protein Care Cell chemokines clinical outcomes clinically Coagulopathy Comorbidities Computerized tomography concerning Coronaviruses COVID-19 COVID-19 infection CoVscoronaviruses criteria CRPC-reactive protein CTcomputerized tomography CXCL10chemokines CXCL9 cytokine D-dimer diagnose Diagnosis diagnostic DICdisseminated intravascular coagulation Digital Disseminated intravascular coagulation distress effective elevated emboli extreme General population GGOground glass opacities gluthathione ground glass opacities GSHgluthathione Health Health authority healthy help high mortality rate highest hypothetical ICUIntensive Care Unit identify IL-10interleukin 10 IL-12interleukin 12 IL-18interleukin 18 IL-1βinterleukin 1 beta IL-33interleukin 33 IL-6interleukin 6 IL-7Interleukin 7 IL-8interleukin 8 immune immune function immunomodulatory implementation increase in individual individuals Inflammation intensive care unit interleukin 1 beta Interleukin 10 interleukin 12 interleukin 18 interleukin 33 interleukin 6 Interleukin 7 interleukin 8 Intervention Isolation Ivermectin lactic dehydrogenase LDHlactic dehydrogenase LDLyme disease literature review Lyme disease macrophage activation syndrome MASmacrophage activation syndrome MERS coronavirus MERS-CovMERS coronavirus morbidity and mortality Multiorgan dysfunction N-acetyl-cysteine NACN-acetyl-cysteine NCPnovel coronavirus pneumonia New NF-κB novel coronavirus pneumonia NSnutritional support nutraceutical nutritional support organ outcomes oxygen Oxygenation pandemic Pathways Patient performed physical distancing Pneumonia precursor Prevent protocol questionnaire Randomized controlled trial randomized trial randomized, controlled trials required resource respiratory therapy resulting risk SARS-CoV-2severe acute respiratory syndrome coronavirus 2 scored screening questionnaire second Sepsis serum severe acute respiratory syndrome coronavirus 2 severe complication silent statistical statistically Stress sulforaphane Support Symptom symptomatic infection TGFβtransforming growth factor beta the disease therapy thrombotic event TNF-αtumor necrosis factor alpha transforming growth factor beta Transmission Treatment Treatment strategies tumor necrosis factor alpha ventilator vital sign Vitamin C WHOWorld Health Organization with COVID-19 World Health Organization
[DOI] 10.1016/j.mehy.2020.109851 [Article Type] Research article